Insights

345 Park Avenue South

Xchange Challenge

All floors are lab-ready and cabled for digital health.

Community

Residents

Leadership

Staff

Neighborhood

Be part of *Cure.*

Orange

Where scientists, entrepreneurs and visionaries converge.

Campus

Ecosystem

Event Spaces

Gallery

Networking hub

Space Availability

A place to *Succeed.*

Green

Joe Wilson How Life Sciences Companies Use AI to Target Investors Mega Menu Image 

Critical Discussions Advancing Healthcare

Events

Event Inquiry

Past Events

Speakers

Tuesday Talks

Cure *Events.*

Magenta

Cure Clips

Tuesday Talks Series

Cure *Tuesday Talks*

Award Finalists to be announced soon!

Partnerships and Sponsorships

Women in Science

XSeed Award

Connect with *Opportunity.*

Blue

Network

Cure Insights Article A Bionic Pancreas that will Help Parents Sleep More Peacefully image for Cure Insights Mega Menu.  Image credit Cottonbro Studio.

A Bionic Pancreas that will Help Parents Sleep More Peacefully

In-depth *Insights.*

About

Contact us

Olorunseun O. Ogunwobi, MD, PhD, is Chair of the Department of Biochemistry and Molecular Biology at Michigan State University College of Human Medicine and co-director of the forthcoming Center for Cancer Health Equity Research at MSU. Ogunwobi previously was a professor of biology at the Hunter College of The City University of New York, founding director and principal investigator of the Hunter College Center for Cancer Health Disparities Research and an adjunct faculty member of the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine. Ogunwobi is also the co-founder of two New York-based startup companies, UTR Therapeutics Inc., a pre-clinical stage biotech company with a first-in-class technology that can overwrite any target of interest; and NucleoBio Inc., a developer of diagnostics tools designed to detect non-invasive urological cancer. He received the XSeed Award in 2023 for work with Chidiebere Awah MD, PhD, on UTR Therapeutics' technology platform to change how we treat cancer. The platform can overwrite and control oncogenic transcript of undruggable c-MYC and HER2 by engineering the 3’UTR and selectively killing cancer over expressing it, including metastatic triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).